182 related articles for article (PubMed ID: 31640304)
1. Proposal of a New Risk Score for Patients Treated with Transarterial Chemoembolization due to Recurrent Hepatocellular Carcinoma after Curative Resection: A Multicenter Study.
Jeon MY; Kim BK; Park JY; Kim DY; Ahn SH; Han KH; Lee JH; Yu SJ; Kim YJ; Yoon JH; Cho EJ; Kim SU
Gut Liver; 2020 Jul; 14(4):477-485. PubMed ID: 31640304
[TBL] [Abstract][Full Text] [Related]
2. Addition of tumor multiplicity improves the prognostic performance of the hepatoma arterial-embolization prognostic score.
Park Y; Kim SU; Kim BK; Park JY; Kim DY; Ahn SH; Park YE; Park JH; Lee YI; Yun HR; Han KH
Liver Int; 2016 Jan; 36(1):100-7. PubMed ID: 26013186
[TBL] [Abstract][Full Text] [Related]
3. Chemoembolization of recurrent hepatoma after curative resection: prognostic factors.
Zu QQ; Liu S; Zhou CG; Yang ZQ; Xia JG; Zhao LB; Shi HB
AJR Am J Roentgenol; 2015 Jun; 204(6):1322-8. PubMed ID: 26001244
[TBL] [Abstract][Full Text] [Related]
4. Complete necrosis after transarterial chemoembolization could predict prolonged survival in patients with recurrent intrahepatic hepatocellular carcinoma after curative resection.
Shim JH; Kim KM; Lee YJ; Ko GY; Yoon HK; Sung KB; Park KM; Lee SG; Lim YS; Lee HC; Chung YH; Lee YS; Suh DJ
Ann Surg Oncol; 2010 Mar; 17(3):869-77. PubMed ID: 20033326
[TBL] [Abstract][Full Text] [Related]
5. Validation and evaluation of clinical prediction systems for first and repeated transarterial chemoembolization in unresectable hepatocellular carcinoma: A Chinese multicenter retrospective study.
Wang ZX; Wang EX; Bai W; Xia DD; Mu W; Li J; Yang QY; Huang M; Xu GH; Sun JH; Li HL; Zhao H; Wu JB; Yang SF; Li JP; Li ZX; Zhang CQ; Zhu XL; Zheng YB; Wang QH; Li J; Yuan J; Li XM; Niu J; Yin ZX; Xia JL; Fan DM; Han GH; On Behalf Of China Hcc-Tace Study Group
World J Gastroenterol; 2020 Feb; 26(6):657-669. PubMed ID: 32103874
[TBL] [Abstract][Full Text] [Related]
6. Predictive performance of the mHAP-II score in a real-life western cohort with hepatocellular carcinoma following trans-arterial chemoembolisation with drug-eluting beads (DEB-TACE).
Peisen F; Maurer M; Grosse U; Nikolaou K; Syha R; Ketelsen D; Artzner C; Bitzer M; Horger M; Grözinger G
Eur Radiol; 2020 Jul; 30(7):3782-3792. PubMed ID: 32125515
[TBL] [Abstract][Full Text] [Related]
7. Feasibility of dynamic risk assessment for patients with repeated trans-arterial chemoembolization for hepatocellular carcinoma.
Park Y; Kim BK; Park JY; Kim DY; Ahn SH; Han KH; Yeon JE; Byun KS; Kim HS; Kim JH; Kim SU
BMC Cancer; 2019 Apr; 19(1):363. PubMed ID: 30991968
[TBL] [Abstract][Full Text] [Related]
8. Refractoriness to transarterial chemoembolization in patients with recurrent hepatocellular carcinoma after curative resection.
Jeon MY; Kim HS; Lim TS; Han DH; Kim BK; Park JY; Kim DY; Ahn SH; Choi GH; Choi JS; Han KH; Kim SU
PLoS One; 2019; 14(4):e0214613. PubMed ID: 30947275
[TBL] [Abstract][Full Text] [Related]
9. Survival outcomes of hepatic resection compared with transarterial chemoembolization or sorafenib for hepatocellular carcinoma with portal vein tumor thrombosis.
Lee JM; Jang BK; Lee YJ; Choi WY; Choi SM; Chung WJ; Hwang JS; Kang KJ; Kim YH; Chauhan AK; Park SY; Tak WY; Kweon YO; Kim BS; Lee CH
Clin Mol Hepatol; 2016 Mar; 22(1):160-7. PubMed ID: 27044767
[TBL] [Abstract][Full Text] [Related]
10. Prognostic Value of Alpha-Fetoprotein in Patients Who Achieve a Complete Response to Transarterial Chemoembolization for Hepatocellular Carcinoma.
Lee JS; Chon YE; Kim BK; Park JY; Kim DY; Ahn SH; Han KH; Kang W; Choi MS; Gwak GY; Paik YH; Lee JH; Koh KC; Paik SW; Kim HY; Kim TH; Yoo K; Ha Y; Kim MN; Lee JH; Hwang SG; Kim SS; Cho HJ; Cheong JY; Cho SW; Park SH; Heo NY; Hong YM; Yoon KT; Cho M; Park JG; Kang MK; Park SY; Kweon YO; Tak WY; Jang SY; Sinn DH; Kim SU;
Yonsei Med J; 2021 Jan; 62(1):12-20. PubMed ID: 33381930
[TBL] [Abstract][Full Text] [Related]
11. Transarterial chemoembolization versus surgery/radiofrequency ablation for recurrent hepatocellular carcinoma with or without microvascular invasion.
Jin YJ; Lee JW; Lee OH; Chung HJ; Kim YS; Lee JI; Cho SG; Jeon YS; Lee KY; Ahn SI; Shin WY
J Gastroenterol Hepatol; 2014 May; 29(5):1056-64. PubMed ID: 24372785
[TBL] [Abstract][Full Text] [Related]
12. Retrospective analysis of transarterial chemoembolization and sorafenib in Chinese patients with unresectable and recurrent hepatocellular carcinoma.
Wan X; Zhai X; Yan Z; Yang P; Li J; Wu D; Wang K; Xia Y; Shen F
Oncotarget; 2016 Dec; 7(50):83806-83816. PubMed ID: 27566566
[TBL] [Abstract][Full Text] [Related]
13. Transarterial chemoembolization versus hepatic resection in hepatocellular carcinoma treatment: a meta-analysis.
Tian X; Dai Y; Wang DQ; Zhang L; Sui CG; Meng FD; Jiang SY; Liu YP; Jiang YH
Drug Des Devel Ther; 2015; 9():4431-40. PubMed ID: 26309396
[TBL] [Abstract][Full Text] [Related]
14. Adjuvant transarterial chemoembolization after curative resection of hepatocellular carcinoma: propensity score analysis.
Jiang JH; Guo Z; Lu HF; Wang XB; Yang HJ; Yang FQ; Bao SY; Zhong JH; Li LQ; Yang RR; Xiang BD
World J Gastroenterol; 2015 Apr; 21(15):4627-34. PubMed ID: 25914472
[TBL] [Abstract][Full Text] [Related]
15. Long-Term Outcomes of Transarterial Chemoembolization Combined with Radiofrequency Ablation Versus Transarterial Chemoembolization Alone for Recurrent Hepatocellular Carcinoma After Surgical Resection.
Song Q; Ren W; Fan L; Zhao M; Mao L; Jiang S; Zhao C; Cui Y
Dig Dis Sci; 2020 Apr; 65(4):1266-1275. PubMed ID: 31312995
[TBL] [Abstract][Full Text] [Related]
16. Combined sequential use of HAP and ART scores to predict survival outcome and treatment failure following chemoembolization in hepatocellular carcinoma: a multi-center comparative study.
Pinato DJ; Arizumi T; Jang JW; Allara E; Suppiah PI; Smirne C; Tait P; Pai M; Grossi G; Kim YW; Pirisi M; Kudo M; Sharma R
Oncotarget; 2016 Jul; 7(28):44705-44718. PubMed ID: 27244889
[TBL] [Abstract][Full Text] [Related]
17. A new ALBI-based model to predict survival after transarterial chemoembolization for BCLC stage B hepatocellular carcinoma.
Lee IC; Hung YW; Liu CA; Lee RC; Su CW; Huo TI; Li CP; Chao Y; Lin HC; Hou MC; Huang YH
Liver Int; 2019 Sep; 39(9):1704-1712. PubMed ID: 31319016
[TBL] [Abstract][Full Text] [Related]
18. Appropriate treatment strategies improve survival of hepatocellular carcinoma patients with portal vein tumor thrombus.
Ye JZ; Zhang YQ; Ye HH; Bai T; Ma L; Xiang BD; Li LQ
World J Gastroenterol; 2014 Dec; 20(45):17141-7. PubMed ID: 25493028
[TBL] [Abstract][Full Text] [Related]
19. Factors predicting long-term outcomes of early-stage hepatocellular carcinoma after primary curative treatment: the role of surgical or nonsurgical methods.
Kuo MJ; Mo LR; Chen CL
BMC Cancer; 2021 Mar; 21(1):250. PubMed ID: 33685409
[TBL] [Abstract][Full Text] [Related]
20. Adjuvant Transarterial chemoembolization does not influence recurrence-free or overall survival in patients with combined hepatocellular carcinoma and Cholangiocarcinoma after curative resection: a propensity score matching analysis.
Liu WR; Tian MX; Tao CY; Tang Z; Zhou YF; Song SS; Jiang XF; Wang H; Zhou PY; Qu WF; Fang Y; Ding ZB; Zhou J; Fan J; Shi YH
BMC Cancer; 2020 Jul; 20(1):642. PubMed ID: 32650743
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
